News
06.08.22

Ocular Science Medical Advisory Board Expands to 30 Leaders in Ophthalmology and Optometry from Around the Country

Physicians William Trattler and Jennifer Loh join the biotech’s leadership team

EL SEGUNDO, Calif. (June 8, 2022) – Southern California biotech Ocular Science® has expanded its national medical advisory board to 30 ophthalmologists and optometrists. William Trattler, MD, and Jennifer Loh, MD, with more than 40 years of experience collectively, are joining a board that establishes strategies to focus on enhanced clinical solutions, products and patient outcomes for Ocular Science and affiliated PCAB-accredited 503A compounding pharmacy, OSRX®.

Dr. Trattler was recognized as one of the “Top 100 most influential people in the world of ophthalmology” in 2016 and was named by Ocular Surgery News as a Premier Surgeon 300 Innovator in Refractive Cataract Surgery. He practices at the Center for Excellence in Eye Care in Miami, Fl. Dr. Trattler was also recognized by his peers as one of the top 50 Cataract and Refractive Surgery Opinion Leaders by the publication Cataract and Refractive Surgery Today in 2006.

Dr. Loh is the founder and medical director at Loh Ophthalmology Associates in Miami, Fla. She has a focus on cataract surgery, refractive cataract surgery, and the management of dry eye disease. She was the recipient of the Rising Star award from Ophthalmic World Leaders in 2018, The Ophthalmologist Power List Rising Star award in 2017 and the Alcon Outstanding Female Leader award in 2016. (For full bios, visit https://www.ocularscience.com/medical-advisory-board.)

“I’m honored and excited to join the Ocular Science medical advisory board. Allowing patients access to high quality compounded medications is important and I look forward to working with a dynamic team of physicians to help provide new solutions in patient care,” said Loh.

“The Ocular Science medical advisory board has an unmatched range of voices, talents and expertise. It’s the who’s who of ophthalmology, serving as our sounding board for nascent research and medical advances,” says Anthony Sampietro, founder and CEO of Ocular Science. “We have rare access to brilliant minds that shepherd our organization and have helped Ocular Science and its affiliate, OSRX, experience record financial growth for five consecutive years.”

OSRX, an Ocular Science affiliate, is a 503A compounding pharmacy that compounds customized (OMNI by OSRX®) ophthalmic medications that are patient-specific and have been prescribed for surgical vision correction, myopia and glaucoma management. OSRX combines multiple medications into a single bottle to provide patients with improved convenience, simplicity and affordability by reducing dosing complexity.

ABOUT OCULAR SCIENCE & OSRX

Ocular Science®, headquartered in El Segundo, Calif., was founded in 2015 by CEO Anthony Sampietro, Chief Medical Officer Damien Goldberg, MD, and Francis Mah, MD. The company is guided by a medical advisory board of world leaders in ophthalmology and focuses on the production, marketing and sales of compounded ophthalmic products. OSRX® – an affiliate of Ocular Science – is a PCAB-accredited 503A compounding pharmacy located in Missoula, Mont. that prepares customized medications in four areas of ophthalmology.

OSRX operates in full compliance with Section 503A regarding compounded drugs as defined in the FD&C Act.

*Compounded drugs are not FDA-approved, which means they have not undergone FDA premarket review for safety, effectiveness, and quality. 503A compounding pharmacies are not required to comply with cGMP requirements but can be inspected by FDA. References available upon request.

Click here to view potential contraindications.